Clinical Trials

  • Principal Investigator:

    Nobuko Hijiya, MD
    The purpose of this study is to learn more about the treatment of children and teenagers whose leukemia has come back (has relapsed) or has not gone away after other treatments (is refractory).Participants will receive the study drug, called carfilzomib in combination with standard chemotherapy, that are dexamethasone, daunorubicin , vincristine and PEG-asparaginase.The study consist of 3 periods: screening, treatment and end of study period.Participants with stable disease or better response at the end of the Induction Cycle will be offered an optional cycle of Consolidation chemotherapy.
  • Principal Investigator:

    Luca Szalontay, MD
    The purpose of this study is to determine if an study drug called pembrolizumab is safe and effective in the treatment of children and adolescents who have advanced melanoma, or advanced, relapsed or refractory PD-L1 positive malignant solid tumor or other lymphoma, relapsed or refractory classical Hodgkin lymphoma (rrcHL), advanced, relapsed or refractory microsatellite-instability-high (MSI-H) solid tumor. Participant might be at least 6 months ( 3 years rrcHL) to less than 18 years old and able to provide the sample for testing the PD-L1 (programmed cell death ligand 1) purpose from an...
  • Principal Investigator:

    Wendy Kay Chung, MD
    Study examining the genetic causes of birth defects.
  • Principal Investigator:

    Wendy Kay Chung, MD
    Study examining the genetic causes of birth defects.
  • Principal Investigator:

    Prakash Satwani, MD
    The COVID-19 Hematology, Oncology, Stem Cell Transplant (HOT) Consortium of Greater New York City is trying to learn more about the effects of COVID-19 on hemoglobinopathies, immunodeficiencies and cancer in children and young adults. Although exact studies for which the Research Database data may be used are not known at this time, the following are types of studies in which these data may be included are: 1) Studies to determine how well people recover from a COVID-19 infection, 2) Studies on how recovery after COVID-19 can be improved, 3) Studies to look at how various demographic and...
  • Principal Investigator:

    Wendy Kay Chung, MD
    Each year more than 1,000 babies in the United States are born with a Congential Diaphragmatic Hernia (CDH). For the majority of these babies, the cause of the CDH is unknown. DHREAMS (Diaphragmatic Hernia Research & Exploration; Advancing Molecular Science) study was created to improve the understanding of the molecular genetic basis of CDH. This National Institute of Health (NIH)-funded research team is composed of health care providers and researchers across the country, coordinated at Columbia University Medical Center. Multiple medical centers are enrolling individuals and families...
  • Principal Investigator:

    Rakesh Sahni, MD
    The purpose of this study is to see if the use of bubble nasal continuous positive airway pressure (NCPAP) at a pressure of 6-7 centimeters of water (cm H2O) in very low birth weight (VLBW) infants is associated with improved gas exchange without any related changes in vital signs.
  • Principal Investigator:

    Stephanie Levasseur, MD
    Although supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The purpose of the FAST Research study is to improve the care of pregnancies affected by AF or SVT. The aim of the FAST Registry is to record the treatment your doctor prescribes, your ongoing care, and the outcome of your...
  • Principal Investigator:

    Stephanie Levasseur, MD
    Although supraventricular tachycardia (SVT), including atrial flutter (AF), are the most common causes of intended in-utero fetal therapy, none of the medication used to date has been evaluated for their effects on the mother and her baby in a randomized controlled clinical trial (RCT). In the absence of such evidence, there is no consensus for the optimal management. The Fetal Atrial Flutter and supraventricular Tachycardia (FAST) Therapy Trial is a prospective multi-center trial that addresses this knowledge gap to guide future fetal atrial flutter & SVT therapy to the best of care.
  • Principal Investigator:

    Vidhu Thaker, MD
    We will enroll children with severe early onset obesity (BMI - 99th percentile) diagnosed prior to 6 years of age. We will ask questions about their health, eating behavior and perform a brief physical examination. We will collect saliva or blood to perform genetic testing. We will also invite family members to participate in the genetic study.

Pages